Markus Zeitlinger

9.9k total citations · 3 hit papers
340 papers, 6.9k citations indexed

About

Markus Zeitlinger is a scholar working on Pharmacology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Markus Zeitlinger has authored 340 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 163 papers in Pharmacology, 87 papers in Epidemiology and 75 papers in Infectious Diseases. Recurrent topics in Markus Zeitlinger's work include Antibiotics Pharmacokinetics and Efficacy (155 papers), Antibiotic Resistance in Bacteria (58 papers) and Drug Transport and Resistance Mechanisms (46 papers). Markus Zeitlinger is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (155 papers), Antibiotic Resistance in Bacteria (58 papers) and Drug Transport and Resistance Mechanisms (46 papers). Markus Zeitlinger collaborates with scholars based in Austria, Germany and United States. Markus Zeitlinger's co-authors include Markus Müller, Peter Marhofer, Peter Matzneller, Oliver Langer, Christian Joukhadar, Daniela Marhofer, Martin Bauer, Edith Lackner, Bernhard Fischer and Hendrik Fischer and has published in prestigious journals such as SHILAP Revista de lepidopterología, Molecular Cell and Gastroenterology.

In The Last Decade

Markus Zeitlinger

321 papers receiving 6.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#

2020 640 citations Sebastian G. Wicha, Markus Zeitlinger et al. profile →
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

2020 319 citations Markus Zeitlinger et al. profile →
Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey

2020 288 citations Susan Tzotzos, Bernhard Fischer et al. Critical Care profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Markus Zeitlinger	2.5k	1.5k	1.3k	1.2k	1.2k	340	6.9k
Carl M. J. Kirkpatrick	2.6k 1.0×	1.6k 1.0×	657 0.5×	925 0.8×	750 0.6×	210	7.7k
Alexander A. Vinks	2.8k 1.1×	1.7k 1.1×	767 0.6×	1.0k 0.9×	893 0.7×	288	8.5k
Daan J. Touw	2.3k 0.9×	1.8k 1.2×	1.1k 0.8×	771 0.6×	944 0.8×	426	9.4k
David E. Nix	2.7k 1.1×	2.7k 1.8×	1.4k 1.1×	1.4k 1.2×	507 0.4×	140	5.8k
Fritz Sörgel	1.8k 0.7×	1.3k 0.8×	723 0.6×	767 0.6×	481 0.4×	144	5.4k
Manjunath P. Pai	2.7k 1.1×	1.9k 1.3×	3.1k 2.5×	681 0.6×	572 0.5×	176	6.6k
Christian Joukhadar	1.9k 0.8×	1.3k 0.9×	1.0k 0.8×	865 0.7×	736 0.6×	100	4.4k
Federico Pea	4.5k 1.8×	2.5k 1.7×	2.3k 1.8×	1.9k 1.6×	664 0.6×	278	7.5k
Jan‐Willem C. Alffenaar	2.9k 1.2×	2.9k 1.9×	4.1k 3.2×	574 0.5×	693 0.6×	284	7.6k
Michael Neely	3.4k 1.3×	2.4k 1.6×	2.7k 2.1×	962 0.8×	341 0.3×	178	6.7k

Countries citing papers authored by Markus Zeitlinger

Since Specialization

Citations

This map shows the geographic impact of Markus Zeitlinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Zeitlinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Zeitlinger more than expected).

Fields of papers citing papers by Markus Zeitlinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Zeitlinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Zeitlinger. The network helps show where Markus Zeitlinger may publish in the future.

Co-authorship network of co-authors of Markus Zeitlinger

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Zeitlinger. A scholar is included among the top collaborators of Markus Zeitlinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Zeitlinger. Markus Zeitlinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hausmann, Bela, et al.. (2025). A Pilot Study on the Impact of Cranberry and Ascorbic Acid Supplementation on the Urinary Microbiome of Healthy Women: A Randomized Controlled Trial. Antibiotics. 14(3). 278–278. 1 indexed citations

Jorda, Anselm, Erdem Yıldız, Maria Weber, et al.. (2025). Immunogenicity, safety, and reactogenicity of concomitant administration of the novavax vaccine against Omicron XBB.1.5 (NVX-CoV2601) and a 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years: A randomised, double-blind, placebo-controlled, non-inferiority trial. Journal of Infection. 90(2). 106405–106405. 1 indexed citations

Simon, Philipp, David Busse, Robin Michelet, et al.. (2025). Evaluation of the need for dosing adaptations in obese patients for surgical antibiotic prophylaxis: a model-based analysis of cefazolin pharmacokinetics. British Journal of Anaesthesia. 134(4). 1041–1049. 2 indexed citations

Rabl, Ulrich, Martin Bauer, Edith Lackner, et al.. (2025). Cerebrospinal fluid concentrations of ceftaroline and ceftazidime/avibactam in healthy volunteers: Pharmacokinetics and probability of target attainment. International Journal of Antimicrobial Agents. 66(2). 107512–107512.

Bambeke, Françoise Van, et al.. (2024). Pharmacokinetic/pharmacodynamic model-based optimization of temocillin dosing strategies for the treatment of systemic infections. Journal of Antimicrobial Chemotherapy. 79(10). 2484–2492. 3 indexed citations

Jorda, Anselm, Ivor S. Douglas, Thomas Staudinger, et al.. (2024). Fluid management for sepsis-induced hypotension in patients with advanced chronic kidney disease: a secondary analysis of the CLOVERS trial. Critical Care. 28(1). 231–231. 5 indexed citations

Bauer, Martin, Iris K. Minichmayr, Birgit Reiter, et al.. (2024). Single‐dose and steady‐state pharmacokinetics of clomipramine, yohimbine and clomipramine/yohimbine combination: A clinical drug–drug interaction study. British Journal of Clinical Pharmacology. 91(3). 808–816.

Marhofer, Peter, Malachy O. Columb, Philipp Opfermann, et al.. (2024). The impact of biological sex in peripheral nerve blockade: A prospective pharmacodynamic, pharmacokinetic and morphometric study in volunteers. PLoS ONE. 19(1). e0297095–e0297095. 1 indexed citations

Marhofer, Peter, et al.. (2024). Liposomal Bupivacaine for Peripheral Nerve Blockade: A Randomized, Controlled, Crossover, Triple-blinded Pharmacodynamic Study in Volunteers. Anesthesiology. 141(1). 24–31. 12 indexed citations

10.

Zeitlinger, Markus, et al.. (2023). Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review. Clinical Pharmacokinetics. 63(1). 13–26. 2 indexed citations

11.

Wulkersdorfer, Beatrix, Felix Bergmann, Edith Lackner, et al.. (2023). Effect of albumin substitution on pharmacokinetics of piperacillin/tazobactam in patients with severe burn injury admitted to the ICU. Journal of Antimicrobial Chemotherapy. 79(2). 262–270. 1 indexed citations

12.

Devreese, Mathias, Markus Zeitlinger, Evelyn Dhont, et al.. (2023). Microdialysis as a safe and feasible method to study target-site piperacillin-tazobactam disposition in septic piglets and children. International Journal of Antimicrobial Agents. 62(5). 106970–106970. 4 indexed citations

13.

Mair, Maximilian J., Rainer Puhr, Marlene Troch, et al.. (2023). Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial. Infectious Agents and Cancer. 18(1). 9–9. 1 indexed citations

14.

Koch, Birgit C. P., et al.. (2023). Population plasma and urine pharmacokinetics and the probability of target attainment of fosfomycin in healthy male volunteers. European Journal of Clinical Pharmacology. 79(6). 775–787. 6 indexed citations

15.

Michelet, Robin, et al.. (2023). Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data. Clinical Pharmacokinetics. 62(10). 1461–1477. 3 indexed citations

16.

Busse, David, Philipp Simon, David Petroff, et al.. (2022). High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients. Antimicrobial Agents and Chemotherapy. 66(6). e0230221–e0230221. 5 indexed citations

17.

Busse, David, Philipp Simon, David Petroff, et al.. (2021). Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients. Clinical Pharmacokinetics. 61(5). 655–672. 10 indexed citations

18.

Busse, David, Philipp Simon, David Petroff, et al.. (2021). Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid Pharmacokinetics. Pharmaceutics. 13(9). 1380–1380. 8 indexed citations

19.

Tzotzos, Susan, Bernhard Fischer, Hendrik Fischer, & Markus Zeitlinger. (2020). Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Critical Care. 24(1). 516–516. 288 indexed citations breakdown →

20.

Lackner, Edith, et al.. (2019). High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis. European Journal of Pharmaceutical Sciences. 131. 218–229. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact